Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC)
Grössmann N
Record ID 32017000332
English
Authors' recommendations:
Overall, the treatment with pembrolizumab offers a statistically significant improvement in OS, independent of the PD-L1 status, with a superior safety profile compared to chemotherapy at high costs. However, due to the early termination of the trial, a systematic overestimation of the treatment effect of pembrolizumab is possible, leading to a need for long-term data. Finally, head-to-head comparison trials comparing pembrolizumab to nivolumab and atezolizumab are essential to investigate which second-line treatment option UC patients benefit the most from.
Details
Project Status:
Completed
URL for project:
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie/en
Year Published:
2017
URL for published report:
http://eprints.hta.lbg.ac.at/1124/1/DSD_HSO_Nr.70.pdf
URL for additional information:
http://eprints.hta.lbg.ac.at/1124/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Antineoplastic Agents, Immunological
- Carcinoma, Transitional Cell
- Antibodies, Monoclonal, Humanized
- Urologic Neoplasms
- Immune Checkpoint Inhibitors
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.